Researchers have shown that those taking part in a home-based exercise programme experienced improvements in their motor symptoms.
New research in rats has shown that alpha-synuclein, an abnormal protein normally found in brain cells affected in Parkinson's, can move rapidly from the gut to the brain. These findings support growing evidence that Parkinson’s may start in the gut rather than the brain.
Researchers have shown that boosting levels of oestrogen in the brains of mice improved symptoms by slowing the build-up of the toxic protein alpha-synuclein.
The Critical Path for Parkinson's meeting brought together pharmaceutical companies, universities, charities and regulatory bodies to address barriers to new treatments.
We’re investing £100,000 to improve compounds that have the potential to boost the function of brain cell batteries and slow the progression of Parkinson’s.
We’re investing nearly £1 million to find a new treatment that targets energy-producing mitochondria to slow the loss of brain cells in Parkinson's.